Login to Your Account



Financings Roundup

Investors Get Bullish on ADCs; Mersana Closes $27M Round

By Catherine Shaffer
Staff Writer

Wednesday, August 1, 2012
Mersana Therapeutics Inc. attracted $27 million in Series A-1 financing for its Fleximer-based antibody-drug conjugate (ADC) pipeline. Riding the coattails of Adcetris' success, Mersana is hoping to develop the next generation of ADCs, addressing limitations of earlier iterations of the technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription